Company Overview

Indegene Limited (BSE: 544172, NSE: INDGN), a leading global healthcare IT services company, published its comprehensive FY26 annual report and financial statements, highlighting strong financial performance, strategic acquisitions, and robust corporate governance practices.

Financial Performance

For FY ended 31 March 2026, Indegene reported consolidated revenue of ₹35,105 million (US$397.4 million), representing 24% growth year-over-year, with net profit of ₹4,011 million. Standalone revenue stood at ₹12,206 million with profit of ₹2,119 million. Key financial metrics include EBITDA of ₹6,247 million, basic EPS of ₹16.72, and operating cash flow of ₹6,508 million. The company maintained healthy ratios with current ratio of 4.66 times and return on equity of 11%.

Corporate Actions and AGM

The Board recommended a final dividend of ₹2.25 per equity share, subject to shareholder approval at the 28th Annual General Meeting scheduled for 13 August 2026. The AGM will address adoption of financial statements, dividend declaration, re-appointment of executive directors Manish Gupta and Dr. Sanjay Suresh Parikh, and appointment of Jill Mary De Simone as independent director for a three-year term. E-voting will be conducted through NSDL from 10-12 August 2026.

Strategic Acquisitions and Business Expansion

Indegene completed four significant acquisitions during FY26: BioPharm Parent Holding, Inc. (US) for ₹8,821 million, Warn and Co Limited (UK), Cake Kommunikations Holding GmbH (Austria), and MJL Communications Group Ltd. These acquisitions contributed goodwill of ₹6,429 million and identifiable intangible assets of ₹2,158 million. The company expanded global delivery centers to London, Pune, and Mumbai, achieving CMMI Level 5 certification and maintaining net revenue retention above 100% with 91 active clients including all top 20 global biopharma companies.

Regulatory and Compliance Matters

The company maintained full compliance with SEBI Listing Regulations and disclosed a draft transfer pricing order proposing ₹1,114 million adjustment for AY 2023-24, which management is contesting through Mutual Agreement Procedure. The company also recognized a ₹203 million provision for a TCPA lawsuit settlement in the US. Auditor Deloitte Haskins & Sells issued unmodified opinions on both financial statements and internal financial controls.

ESG Performance and Corporate Responsibility

Indegene demonstrated strong ESG commitment with a Business Responsibility and Sustainability Report showing 20.63% reduction in Scope 1 & 2 emissions, 68.68% reduction in Scope 3 emissions, 65.3% renewable energy consumption, and 69% waste recycling. The company received external ratings including CDP 'B' score, EcoVadis Silver Medal (75), and NSE ESG score of 80 (Leader category). CSR expenditure met the required ₹36 million, focused on education, health, and technology initiatives.

Capital Structure and Shareholding

The company's issued share capital remained unchanged at ₹48,18,02,708 divided into 24,09,01,354 equity shares. Promoters held 0% stake while foreign companies held 33.62% and public held 12.56% as of 31 March 2026. IPO proceeds utilization reached 99.7% completion with ₹172 million remaining unutilized. Employee strength stood at 5,666 with 16.35% voluntary attrition rate.

Outlook and Future Prospects

With completed acquisitions, expanded delivery capabilities, and strong client relationships, Indegene is positioned for continued growth in the healthcare IT services sector. The company's focus on innovation, regulatory compliance, and sustainable practices supports its long-term strategic objectives in serving the global pharmaceutical and healthcare industries.